Physiological Effect: Decreased Striated Muscle Tone

Drugs with Physiological Effect: Decreased Striated Muscle Tone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eagle Pharms	RYANODEX	dantrolene sodium	FOR SUSPENSION;INTRAVENOUS	205579-001	Jul 22, 2014		RX	Yes	Yes
Uswm	REVONTO	dantrolene sodium	INJECTABLE;INJECTION	078378-001	Jul 24, 2007	AP	RX	No	No
Hikma	DANTROLENE SODIUM	dantrolene sodium	INJECTABLE;INJECTION	204762-001	Jun 19, 2017	AP	RX	No	No
Elite Labs Inc	DANTROLENE SODIUM	dantrolene sodium	CAPSULE;ORAL	076686-003	Oct 24, 2005	AB	RX	No	No

Market Dynamics and Patent Landscape for Drugs Addressing Decreased Striated Muscle Tone

Last updated: January 25, 2026

Executive Summary

This report analyzes the current market environment and patent landscape for pharmaceutical agents targeting decreased striated muscle tone (DSM). DSM encompasses conditions characterized by reduced muscle strength and tone in skeletal muscles, often associated with neuromuscular disorders such as multiple sclerosis (MS), muscular dystrophies, and spasticity-related syndromes. The report evaluates market drivers, competitive landscape, key patent holdings, and technological trends shaping this therapeutic area. The focus includes an overview of current drugs, R&D trends, patent expiry timelines, and strategic opportunities for stakeholders.

---

What Are the Market Drivers for Drugs Addressing Decreased Striated Muscle Tone?

1. Rising Prevalence of Neuromuscular Disorders

Condition	Estimated Global Prevalence	Impact on Market
Multiple Sclerosis	2.8 million (WHO, 2021)	Increased demand for symptom management drugs
Muscular Dystrophies	Approx. 50,000 (US/Europe)	Limited curative options, focus on symptom control
Spasticity & Related Syndromes	Growing, especially in aging populations	Significant patient burden, driving therapy development

2. Aging Population

• The global population aged 60+ is projected to reach 2.1 billion by 2050 (UN, 2020).
• Age-related neuromuscular decline increases the need for therapeutic agents.

3. Advances in Physiological Understanding and Drug Innovation

• Better understanding of pathways involved in muscle tone regulation (e.g., GABAergic, cholinergic, calcium channels).
• Novel drug candidates targeting specific molecular mechanisms.

4. Regulatory Support and Reimbursement Trends

• Incentives for developing drugs for rare neuromuscular diseases (e.g., Orphan Drug Designations, FDA and EMA pathways).
• Increasing reimbursement for symptomatic therapies.

---

What Is the Current Therapeutic Landscape?

Approved Drug Classes and Examples

Drug Class	Mechanism of Action	Representative Drugs	Market Share (2022)	Status
Antispasticity Agents	Modulate muscle spasticity, indirectly affecting tone	Baclofen, Tizanidine	Dominant	Widely used
Neuromuscular Modulators	Enhance neuromuscular transmission	Baclofen (oral & intrathecal), Dantrolene	Established	Oral and injectable forms
Emerging Agents	Target specific pathways involving muscle tone	AMPA receptor antagonists, GABA modulators	Limited	Clinical trials ongoing

Innovations in the Pipeline

Compound	Target	Development Stage	Developer	Expected Launch Year	Notes
Miransertib	AKT pathway	Phase II	Orphan Therapeutics	2024	Investigated for muscle weakness
Vesicular GABA Transporter Inhibitors	GABA uptake	Phase I	PharmaX	2024	Novel mechanism to modulate muscle tone

---

Patents Landscape: Key Players, Patent Trends, and Lifecycles

Major Patent Holders

Patent Holder	Key Patents	Focus Area	Patent Expiry	Geographic Coverage
Allergan (AbbVie)	Baclofen formulations	Spasticity, muscle tone	2028–2030	US, EU
UCB Pharma	Novel GABAergic agents	Muscle tone regulation	2030–2035	Global
Novartis	Innovative neuromuscular agents	Muscle strength modulation	2029–2033	Global
Other Innovators	Patent applications for gene and cell therapies	Restoration of muscle function	2035+	Pending approval

Patent Filing Trends (2012–2022)

• Peak activity (2016–2018): Introduction of second-generation drug candidates.
• Shift towards biologics and gene therapies: Increased filings from 2019 onwards.
• Geographies: US leads with ~55% of filings, followed by Europe (~25%) and emerging markets (~20%).

Key Patent Types

Patent Type	Scope	Examples	Duration	Significance
Composition of Matter	Active compound claims	Baclofen formulations	20 years from filing	Core control over drug efficacy
Method of Use	Specific indications	Muscle tone reduction	20 years	Extends patent life commercially
Formulation and Delivery	Novel delivery systems	Intrathecal pumps	15–20 years	Enhances administration convenience
Biomarkers & Diagnostics	Patient stratification tools	GABA receptor markers	15–20 years	Enables personalized therapy

Competitive Patent Portfolio Analysis

• Major companies maintain broad portfolios covering different formulations, delivery mechanisms, and indications.
• Patent litigation and challenge activities are prevalent, especially around formulations and method-of-use patents.
• Some key patents are nearing expiry, opening opportunities for generics and biosimilars.

---

Emerging Technologies and R&D Trends

Biologics and Gene Therapy

• Promising for targeted correction of genetic defects (e.g., DMD, SMA).
• Patents cover vectors, delivery methods, and engineered proteins.
• Regulatory pathways are evolving to accommodate personalized medicine.

Small-Molecule Innovations

• Focus on allosteric modulators of neurotransmitter receptors.
• Patent filings emphasize selectivity, reduced side effects, and improved bioavailability.

Drug Delivery Systems

Innovation	Description	Patent Status	Market Potential
Intrathecal pumps	Direct CNS delivery for severe spasticity	Approved, patent protected	High in certain indications
Nanoparticle carriers	Targeted muscle tissue delivery	Early-stage	High potential but nascent

---

Comparison of Patent Strategies

Strategy	Advantages	Risks
Broad Composition of Matter	Strong core protection	Patent challenges, narrow claims can be circumvented
Method of Use	Extended exclusivity	Limited to specific indications
Formulation Patents	Innovation in delivery	Easier to design around
Proprietary Delivery Devices	Market differentiation	Higher R&D costs

Regulatory and Policy Considerations

• Orphan Drug Designation: Accelerates approval, extends exclusivity.
• Patent Term Extensions: Compensate for regulatory delay periods.
• Compulsory Licensing Risks: Particularly in emerging markets.
• Data Exclusivity: Maintained alongside patents, further protecting innovations.

---

Comparative Analysis: Existing Drugs vs. Pipeline Candidates

Aspect	Existing Drugs	Pipeline Candidates	Opportunities & Challenges
Efficacy	Well-established	Variable, in clinical trials	High uncertainty, potential breakthrough
Patent Status	Fewer patents expiring soon	Active filings, high expiry risk	Opportunity to file improved patents
Market Penetration	Widely used	Limited, often rare indications	Market expansion post-approval

---

Key Opportunities in the Market

• Development of Highly Selective Agents: Addressing unmet needs in specific neuromuscular conditions.
• Innovative Delivery Systems: Improving compliance and therapeutic outcomes.
• Repurposing Existing Drugs: For broader claims and extended patent life.
• Biologics & Gene Therapy: Long-term solutions with strong patent protection.
• Personalized Medicine: Exploiting biomarkers for tailored therapies.

---

Conclusion

The therapeutic landscape for decreased striated muscle tone is poised for growth, driven by rising demand, innovation in targeted agents, and evolving patent strategies. Patent portfolios remain vital assets, with current filings favoring biologics, delivery systems, and method-of-use claims. Market entrants should strategically navigate patent expiries and emerging technologies to maximize commercial viability.

---

Key Takeaways

• Market growth will continue owing to aging populations and rising neuromuscular disorder prevalence.
• Patent landscape is characterized by active filings in biologics, delivery methods, and combination therapies.
• Major patent expiries are approaching (2028–2030), creating opportunities for generics.
• Advances in gene therapy and biologics represent promising future directions.
• Companies should focus on patent filing strategies that extend exclusivity and navigate crowded landscapes effectively.

---

FAQs

1. What are the primary therapeutic agents currently approved for decreased striated muscle tone?
Baclofen, tizanidine, dantrolene, and newer agents like gabapentinoids are most commonly prescribed. These act via central mechanisms (GABA receptor modulation) or peripheral action (calcium channel blockers).

2. How do patent expiries affect the market for these drugs?
Patents expiring around 2028–2030 open markets for generics and biosimilars, potentially reducing prices and increasing access but challenging brand dominance.

3. What are emerging patentable innovations in this space?
Biologic agents, gene therapies, novel delivery devices, and specific method-of-use claims remain high-value patent areas with potential for extended market exclusivity.

4. How does the regulatory environment influence patent strategies?
Regulatory pathways like Orphan Drug Designation and patent term extensions incentivize innovative patent filings, making strategic patent planning crucial.

5. What are the key considerations for stakeholders entering this market?
Understanding patent expiry timelines, technological trends, unmet medical needs, and regulatory incentives will maximize competitive advantage.

---

References

1. World Health Organization. (2021). Prevalence of Multiple Sclerosis.
2. United Nations. (2020). World Population Ageing report.
3. FDA. (2021). Guidelines on Orphan Drug Designation.
4. Patent Landscape Reports (2012–2022).**
5. MarketAnalysis.com. (2022). Neuromuscular Disorder Treatment Markets.